v3.26.1
Fair Value of Financial Assets and Liabilities - Schedule of Liabilities with Unobservable Inputs (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jan. 31, 2026
Jan. 31, 2025
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag true  
Technical Milestone Contingent Consideration    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance [1] $ 5,980 $ 5,114
Additions [1] 0 0
Payments [1] (3,250) 0
Transfers out of Level 3 [1],[2],[3] 2,919  
Change in fair value [1] 189 866
Ending balance [1] 0 5,980
Customer Contract Earnout Contingent Consideration    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance [1] 1,578 1,926
Additions [1] 0 0
Payments [1] (1,570) (1,270)
Transfers out of Level 3 [1],[2],[3] 284  
Change in fair value [1] 276 922
Ending balance [1] 0 1,578
Customer Consent Escrow Contingent Consideration    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance [1] 0 5,851
Additions [1] 0 0
Payments [1] 0 (7,500)
Transfers out of Level 3 [1],[2],[3] 0  
Change in fair value [1] 0 1,649
Ending balance [1] (0) 0
Private Placement Warrants    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance 8,900 1,305
Additions 0 0
Payments 0 0
Transfers out of Level 3 [2],[3] 5,734  
Change in fair value 41,779 7,595
Ending balance $ 44,945 $ 8,900
[1] The current portion of the contingent consideration liabilities balances of $4.7 million as of January 31, 2025, is included within accrued and other current liabilities. Changes in fair value of the contingent consideration liability for the Salo Sciences technical milestone payments are included within research and development expenses. Changes in fair value of the Salo Sciences contingent consideration liability for customer contract earnout payments are included within sales and marketing expenses. Changes in fair value of the contingent consideration liability for the Sinergise acquisition customer consent escrow payments are included within general and administrative expenses.
[2] During the fiscal year ended January 31, 2026, the Company transferred 2,966,666 Private Placement Warrants from Level 3 to Level 1. The warrants were transferred to Level 1 due to the removal of the restrictive legends from the Private Placement Warrants, resulting in such warrants being able to be sold in the active market. The Company's policy is to recognize transfers between fair value hierarchy levels at the beginning of the reporting period during which the transfer occurred.
[3] During the fiscal year ended January 31, 2026, the Company transferred the contingent consideration liabilities for technical milestone payments and customer contract earnout payments out of Level 3 to a legal contingency accrual in accordance with ASC 450. The liability was transferred due to the probable settlement expected to extinguish any contractual amounts owed for the acquisition, inclusive of the contingent consideration liabilities balance. Refer to Note 10.